Dominari (NASDAQ:DOMH) Stock Rating Lowered by Wall Street Zen

Dominari (NASDAQ:DOMH) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dominari in a research note on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Dominari Price Performance

Dominari stock opened at $2.71 on Friday. The company has a market cap of $65.69 million, a price-to-earnings ratio of -0.50 and a beta of 0.87. The firm has a 50-day moving average of $2.88 and a 200-day moving average of $3.11. Dominari has a one year low of $2.19 and a one year high of $8.40.

Dominari (NASDAQ:DOMH) last released its earnings results on Monday, August 10th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.13. Dominari had a negative return on equity of 235.37% and a negative net margin of 51.61%.The business had revenue of $16.79 million for the quarter, compared to the consensus estimate of $16.79 million.

Hedge Funds Weigh In On Dominari

A number of hedge funds and other institutional investors have recently bought and sold shares of DOMH. Geode Capital Management LLC increased its position in Dominari by 2.9% during the second quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after buying an additional 1,866 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Dominari in the second quarter valued at approximately $158,000. Vanguard Group Inc. boosted its stake in shares of Dominari by 8.0% during the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock worth $2,452,000 after acquiring an additional 25,694 shares during the period. Two Sigma Investments LP bought a new position in shares of Dominari during the 3rd quarter worth approximately $771,000. Finally, Millennium Management LLC acquired a new position in shares of Dominari during the 3rd quarter worth approximately $213,000. Institutional investors own 42.48% of the company’s stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2.